ArticlePatterns (New York, N.Y.)2026
A self-supervised framework for emphysema anomaly detection and staging in computed tomography scans.
Article in Patterns (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emphysema, a diffuse and heterogeneous phenotype of chronic obstructive pulmonary disease (COPD), carries substantial morbidity and elevates lung cancer risk. While computed tomography (CT) aids in detection and monitoring, current deep learning methods depend on large annotated datasets. Unsupervised anomaly detection (UAD) provides an alternative but faces challenges with emphysema anomalies and weak emphysema semantics. In this study, we propose a self-supervised framework trained exclusively on non-emphysema CT scans using synthetically generated lesions to guide pixel-level anomaly modeling. We introduce EDLNet, an encoder-decoder architecture with spatial-channel refinement and adaptive feature fusion for emphysema detection and localization, followed by an unsupervised manner for emphysema staging. Multi-center evaluations show that our framework outperforms existing UAD approaches in detection and localization, while achieving a mean staging accuracy of 93.13% and a macro AUROC of 99.08%. This approach bridges clinical knowledge and artificial intelligence, offering a scalable and interpretable solution for lung disease analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.